More MS news articles for April 2001

Update: Health Technology Appraisal: beta interferon and glatiramer acetate in the treatment of Multiple Sclerosis

Members of the Instituteís Appraisal Committee Institute staff and the consortium appointed to undertake the additional modelling on the beta interferons and multiple sclerosis for MS are meeting consultees today, 30 March, to discuss how the modelling is to be developed.

The Institute has appointed a consortium based on the Sheffield School of Health and Related Research (ScHARR) and the Department of Mathematics and Statistics at the University of Sheffield working with colleagues from Oxford, City, Newcastle Nottingham and York Universities to undertake the work, which the Appraisal Committee will see the results of in July.

The Institute has asked the manufacturers of the beta interferons and glatiramer acetate to contribute to the work both by commenting on the consortiumís methodology and by providing clinical trial data. Patient and professional group consultees have also been invited to contribute.